Division of Pediatric Hematology and Oncology.
Division of Pediatric Infectiology, Department of Pediatrics.
J Pediatr Hematol Oncol. 2021 Aug 1;43(6):e804-e807. doi: 10.1097/MPH.0000000000001943.
The clinical course of SARS-CoV-2 infection (COVID-19) in children with hematologic malignancies is unclear. We describe the diagnosis, treatment and outcome of a 4-year-old boy with high-risk acute lymphoblastic leukemia and COVID-19. Regardless of immunosuppressive induction chemotherapy his symptoms remained moderate. He received only supportive treatment. Seroconversion occurred in a similar period as in immunocompetent adults. Despite prolonged myelosuppression he did neither acquire secondary infections nor did the treatment delay caused by the infection have a measurable negative impact on the residual disease of acute lymphoblastic leukemia. Intriguingly, residual leukemia even decreased even though he did not receive any antileukemic therapy.
儿童血液恶性肿瘤患者感染 SARS-CoV-2（COVID-19）的临床过程尚不清楚。我们描述了一名 4 岁高危急性淋巴细胞白血病合并 COVID-19 患儿的诊断、治疗和结局。尽管接受了免疫抑制诱导化疗，但他的症状仍保持中度。他仅接受了支持治疗。与免疫功能正常的成年人一样，他在相似的时间发生了血清转换。尽管骨髓抑制持续时间较长，但他既没有继发感染，也没有因感染而导致治疗延迟，对急性淋巴细胞白血病的残留疾病产生可衡量的负面影响。有趣的是，尽管他没有接受任何抗白血病治疗，残留白血病甚至减少了。
